Business, energy, technology, markets and global industry news from Business News Today

Taiwan

PharmaDeviceNews Taiwan
Representative image showing a prostate cancer research and testing environment, aligned with our coverage of Rubraca’s FDA approval and its Phase 3 TRITON3 trial results in BRCA-mutated metastatic castration-resistant prostate cancer.
Pharma & Biotech

China approves Foresee’s twice-yearly prostate cancer injection. Could it unlock a $123.85m milestone deal?

Foresee's CAMCEVI 42 mg wins China approval for advanced prostate cancer. Examine GeneScience's launch plans, clinical evidence and licensing economics.

Read More
Galderma expands Alastin professional skincare across Japan and key Asia Pacific medical aesthetics markets as demand for procedure-linked skincare grows. Representative image.
Pharma & Biotech

Galderma is taking Alastin deeper into Asia, but this launch is about more than skincare

Galderma expands Alastin across Japan and Asia Pacific, linking premium skincare with rising demand for aesthetic procedures.

Read More